PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-02-12 zhang92560

#Onvasertib#

73 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2021-01-07 LShY0906_98743851

#mCRC#

124 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-09-24 朱睿睿

#临床获益#

68 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-12-11 jklm09

#抑制剂#

83 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-03-02 yxch36

#CRC#

68 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-01-30 1478fa69m73暂无昵称

学习了

118 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-01-30 ms5906905816781247

#KRAS突变#

106 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-01-30 yinhl1978

#KRAS#

60 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-01-30 bioon7

#RAS突变#

93 0

[GetPortalCommentsPageByObjectIdResponse(id=2025186, encodeId=2fc62025186fc, content=<a href='/topic/show?id=027413391d7' target=_blank style='color:#2F92EE;'>#Onvasertib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13391, encryptionId=027413391d7, topicName=Onvasertib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7460166, createdName=zhang92560, createdTime=Wed Feb 12 08:38:00 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11396, encryptionId=b70711396cd, topicName=mCRC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c9723008141, createdName=LShY0906_98743851, createdTime=Thu Jan 07 13:38:00 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040403, encodeId=5a102040403b2, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu Sep 24 03:38:00 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852257, encodeId=c280185225e39, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Dec 11 14:38:00 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827258, encodeId=f35d182e25885, content=<a href='/topic/show?id=52e95194b9' target=_blank style='color:#2F92EE;'>#CRC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5194, encryptionId=52e95194b9, topicName=CRC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon Mar 02 17:38:00 CST 2020, time=2020-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378690, encodeId=81c43e8690c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/13/297abc49521542fee373596e497d37fc.jpg, createdBy=db695226500, createdName=1478fa69m73暂无昵称, createdTime=Thu Jan 30 14:16:46 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332867, encodeId=e0e6133286e17, content=<a href='/topic/show?id=e070105e2bb' target=_blank style='color:#2F92EE;'>#KRAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10572, encryptionId=e070105e2bb, topicName=KRAS突变)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/17F844FBE270B8196CB4C53EC9493C57/100, createdBy=9d712500079, createdName=ms5906905816781247, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369015, encodeId=f91e1369015d3, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10567, encryptionId=13cb1056e20, topicName=KRAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585322, encodeId=b857158532234, content=<a href='/topic/show?id=792b15145a6' target=_blank style='color:#2F92EE;'>#RAS突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15145, encryptionId=792b15145a6, topicName=RAS突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f2c17156536, createdName=bioon7, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602831, encodeId=b09b160283116, content=<a href='/topic/show?id=01c21438274' target=_blank style='color:#2F92EE;'>#PLK1抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14382, encryptionId=01c21438274, topicName=PLK1抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=857118955686, createdName=zhangjingnwpu, createdTime=Thu Jan 30 11:38:00 CST 2020, time=2020-01-30, status=1, ipAttribution=)]

2020-01-30 zhangjingnwpu

#PLK1抑制剂#

69 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化

PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益

相关资讯

科室

工具

服务